万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>肿瘤学

Cancer Management and Research《癌症管理与研究》 (官网投稿)

简介
  • 期刊简称CANCER MANAG RES
  • 参考译名《癌症管理与研究》
  • 核心类别 SCIE(2023版), 目次收录(知网),外文期刊,
  • IF影响因子
  • 自引率3.30%
  • 主要研究方向医学-ONCOLOGY肿瘤学

主要研究方向:

等待设置主要研究方向
医学-ONCOLOGY肿瘤学

Cancer Management and Research《癌症管理与研究》(不定期). Cancer Management and Research is an international, peer reviewed, open access journal focusin...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://www.dovepress.com/cancer-management-and-research-journal

3、投稿网址:

https://www.dovepress.com/submit_step_1.php

4、期刊刊期:不定期出版。

2022112日星期三

                              

 

投稿须知【官网信息】

 

Cancer Management and Research

Aims and Scope

Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients.

Cancer Management and Research will no longer consider meta-analyses for publication.

Specific topics covered in the journal include:

Epidemiology, detection and screening

Cellular research and biomarkers

Identification of biotargets and agents with novel mechanisms of action

Optimal clinical use of existing anticancer agents, including combination therapies

Radiation and surgery

Palliative care

Patient adherence, quality of life, satisfaction

The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.

When considering submission of a paper utilizing publicly-available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria.

The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Cell line studies must demonstrate thorough and rigorous protocols, and biomarker association studies must be supported by in vivo validations. Tissue microarray analyses and single nucleotide polymorphism (SNP) studies will not be considered.

 

Call For Papers

To see where Cancer Management and Research is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Cancer Management and Research?

It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.

Although Cancer Management and Research receives many papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.

The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Cancer Management and Research has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.

Many authors have found that our peer reviewers’ comments substantially add to their final papers.

To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution a publication processing fee.

PubMed

Cancer Management and Research is indexed on PubMed Central (title abbreviation Cancer Manag Res). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits

If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.

Yours sincerely

Dr Kenan Onel

Editor-in-Chief

Cancer Management and Research

Email: Editor-in-Chief

 

Author Guidelines

In this section you will find information on the entire submission process for Dovepress Journals. This includes how to format the paper, the language guidelines, referencing, the use of data & clinical trials and the acceptance process. These resources ensure the quality of the journal submissions and that the articles have the best chance of acceptance.

A summary of some of these sections are:

Manuscript preparation

This provides guidelines to the formatting requirements for a submission to Dove Medical Press, with instructions for formatting the document (margins, spacing, etc) and the text (spelling, abbreviations, etc).

Manuscript template

The template provided at this link can be used to ensure that the manuscript meets Dove specifications for formatting and structure of the text. The template can be downloaded and saved to your computer.

Manuscript structure

This section contains a detailed breakdown of each section that the manuscript will contain, as well as all disclosures and acknowledgements that are required by Dove Medical Press. The section also includes criteria for inclusion in the author list.

Figures and tables

This contains specifications for the formatting of figures and tables, including technical requirements such as file types and naming, and graphic requirements such as font size and image resolution.

Clinical trial registration

This provides a clear definition that authors may use to determine if their study will be considered a clinical trial. The section sets out Dove’s requirements for registration of any clinical trial involving human subjects.

……

更多详情:

https://www.dovepress.com/author-guidelines


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭